Symptom Monitoring

2

Review clinical trials related to Symptom Monitoring. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

mHealth Intervention for Pain Self Management

This is a feasibility pilot test of a single-arm intervention to evaluate the beta version of an mHealth app-based behavioral intervention prior to scaling for a randomized controlled trial (RCT). This mHealth intervention is designed to enhance self-efficacy and support pain and symptom self-management among post-treatment cancer survivors.

Participants needed: 25
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Virginia Commonwealth UniversityUpdated: Mar 18, 2026Locations: 1
Eligibility criteria

In a post-treatment stage with no evidence of disease (complete remission) [+5]

Individuals who currently use any medication for psychiatric reasons (including... [+2]

Status: Not yet recruiting

Mitigating Toxicity by Electronic Health Portal-mediated Interactive Monitoring of Patient-reported Side Effects

Chemotherapy induces side effects varying in severity, impacting patients' quality of life and necessitating unplanned hospital care. Patient-reported outcomes (PROs) could aid in early detection and management of side effects. However, existing PRO monitoring lacks triage capabilities, leading to clinician involvement and suboptimal symptom management. The investigators propose eChemoCoach, an electronic questionnaire integrated into the electronic health portal, offering real-time symptom assessment and personalized advice based on CTCAE criteria. Our study aims to assess the impact of eChemoCoach on non-hematological CTCAE ≥ 3 graded side effects in early breast cancer patients undergoing chemotherapy. This is a randomized controlled trial involving 746 patients that will evaluate the eChemoCoach's efficacy compared to standard monitoring. Phase one will validate questionnaires and assess usability, while phase two focuses on the primary outcome. Te investigators anticipate reduced severe side effects, thereby enhancing patients' quality of life, reducing stress, and minimizing hospital visits.

Participants needed: 746
Trial details
Age: 18+Biological sex: AllType: InterventionalSponsor: Noordwest ZiekenhuisgroepUpdated: May 21, 2024
Eligibility criteria

Four cycles of doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 (AC) dose dense... [+5]

- Participation in a trial with an investigational product (because more frequen... [+2]